Research programme: single domain antibodies - Argenta/Domantis

Drug Profile

Research programme: single domain antibodies - Argenta/Domantis

Alternative Names: Single domain antibodies research programme - Argenta/Domantis

Latest Information Update: 20 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argenta Discovery; Domantis
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Respiratory tract disorders

Most Recent Events

  • 07 Jan 2007 Domantis has been acquired by GlaxoSmithKline
  • 10 Nov 2006 Preclinical development is still ongoing
  • 26 Oct 2004 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top